21 completed, 7 active not recruiting, 4 unknown, 2 recruiting. 17 Phase 2, 8 Phase 1, 8 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Endometrial Serous Adenocarcinoma: new trials by email Literature Review of Endometrial Serous Adenocarcinoma trials Research Report on Endometrial Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMT-151 in Patients With Selected Advanced Solid Tumours AMT-151 - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Unknown | Multitude Therapeutics Inc. | 30 | 2023-01-25 | 2023-10-19 |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Biospecimen Collection, Carboplatin, Computed Tomography - Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 360 | 2022-11-16 | 2026-10-02 |
| Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy Biopsy Procedure, Biospecimen Collection, Resection - Endometrial Serous Adenocarcinoma | Early Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2022-02-08 | 2026-06-11 |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer Carboplatin, Computed Tomography, Paclitaxel - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 813 | 2019-08-22 | 2026-10-21 |
| Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers Biospecimen Collection, Liquid Biopsy, Pap Smear - Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma | Recruiting | M.D. Anderson Cancer Center | 1000 | 2019-06-18 | 2026-10-07 | |
| Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer Mirvetuximab Soravtansine, Bevacizumab - Endometrial Cancer, Endometrial Adenocarcinoma | Phase 2 | Withdrawn | University of Oklahoma | 2019-05-31 | 2019-06-27 | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 288 | 2018-09-27 | 2026-10-22 |
| Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer Vaginal Cuff Brachytherapy, Short course vaginal cuff brachytherapy - Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma | Phase 3 | Recruiting | University of Utah | 188 | 2018-02-02 | 2025-12-12 |
| Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer Copanlisib, Laboratory Biomarker Analysis - Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma | Phase 2 | Completed | NRG Oncology | 11 | 2016-09-16 | 2022-02-15 |
| Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Metformin Hydrochloride, Doxycycline - Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 29 | 2016-06-08 | 2026-04-22 |
| Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Cisplatin, Carboplatin, Paclitaxel - Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma | Phase 3 | Completed | Women's Cancer Care Associates, LLC | 48 | 2015-03-01 | 2024-07-23 |
| Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery Comprehensive Geriatric Assessment, Questionnaire Administration - Endometrial Serous Adenocarcinoma, Fallopian Tube Carcinoma | Completed | NRG Oncology | 190 | 2015-02-10 | 2021-11-24 | |
| TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study - Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 50 | 2014-05-20 | 2026-08-28 |
| Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Paclitaxel, Carboplatin, 3-Dimensional Conformal Radiation Therapy - Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer | Phase 2 | Terminated | Albert Einstein College of Medicine | 4 | 2014-04-10 | 2023-08-29 |
| Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 / Phase 3 | Unknown | Gynecologic Oncology Group | 469 | 2014-03-17 | 2021-09-30 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Laboratory Biomarker Analysis, Trametinib, Uprosertib - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2013-09-30 | 2020-10-14 |
| Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 102 | 2013-05-08 | 2025-10-01 |
| PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer Computed Tomography, Indocyanine Green Solution, Laboratory Biomarker Analysis - Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 101 | 2013-04-03 | 2026-10-08 |
| Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Dalantercept, Laboratory Biomarker Analysis - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Completed | Gynecologic Oncology Group | 28 | 2012-09-01 | 2018-03-13 |
Showing 20 of 37. Sign in to see all of them.
Carcinoma, Endometrioid (4) · Endometrial Neoplasms (4) · Ovarian Neoplasms (4) · Fallopian Tube Neoplasms (3) · Carcinosarcoma (2) · Neoplasms (2) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Fatigue (1) · Glioblastoma (1) · Mesothelioma, Malignant (1) · Mixed Tumor, Mesodermal (1)
Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Genital Diseases (13) · Genital Diseases, Female (13) · Genital Neoplasms, Female (13) · Neoplasms (13) · Neoplasms by Site (13) · Urogenital Diseases (13) · Urogenital Neoplasms (13) · Neoplasms by Histologic Type (10) · Uterine Neoplasms (9) · Adnexal Diseases (8) · Endocrine System Diseases (8) · Gonadal Disorders (8) · Ovarian Diseases (8)
Paclitaxel (13) · Taxes (12) · Carboplatin (10) · Cisplatin (7) · Bevacizumab (6) · Disulfides (6) · Immunoglobulin G (6) · Radiation (4) · Radiotherapy (4) · Brachytherapy (3) · Doxorubicin (3) · Radiotherapy, Intensity-Modulated (3) · Specimen Handling (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Biopsy (2)
National Cancer Institute (NCI) (14) · Gynecologic Oncology Group (12) · M.D. Anderson Cancer Center (2) · NRG Oncology (2) · Albert Einstein College of Medicine (1) · Mayo Clinic (1) · Multitude Therapeutics Inc. (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Oklahoma (1) · University of Utah (1) · Women's Cancer Care Associates, LLC (1)
United States (36) · Canada (9) · South Korea (4) · Puerto Rico (2) · Australia (1) · China (1) · Hong Kong (1) · Japan (1)
D. McMeekin (2) · Akila Viswanathan (1) · Alessandro D Santin (1) · Amina Ahmed (1) · Amit M Oza (1) · Barbara Buttin (1) · Britt K Erickson (1) · Carol Aghajanian (1) · Catherine Shannon (1) · Cristina DeCesaris, MD (1) · Daniela E Matei (1) · David Bender (1) · Don Dizon (1) · Helen J Mackay (1) · Henry Pitot (1)
PMID 24882554, PMID 25312396, PMID 25318437, PMID 25488966, PMID 25847373, PMID 30995174, PMID 31189035, PMID 31714586, PMID 31992589, PMID 33541735, PMID 34903380, PMID 35658479, PMID 36972022, PMID 37411031, PMID 37702588, PMID 38127487, PMID 38431043, PMID 39700442, PMID 40044930, PMID 40966692
U10CA027469 (15), U10CA180868 (15), P50CA098258 (3), N01CM00032 (2), N01CM00038 (2), N01CM00071 (2), N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), P30CA006516 (2), U01CA062490 (2), UM1CA186709 (2), N01CM00039 (1), N01CM00070 (1), N01CM00099 (1)